Paclitaxel/Taxol prevents microtubule disassembly, resulting in cell cycle arrest and apoptosis. It is used clinically as a frontline therapy for ovarian tumors and has shown increasing efficacy in the treatment of breast cancer. The most encouraging data were obtained with a combination therapy using paclitaxel and anti-Her2/neu antibody. However, improvements in combination therapy with paclitaxel/Taxol for the treatment of breast cancer are still needed. Our past effort has focused on the effects of paclitaxel on gene expression signaling and apoptosis in epithelial cancer cells. We first found that paclitaxel induces the JNK/SAPK kinase system in breast carcinomas, and this activation is involved in paclitaxel-induced apoptosis. In contrast paclitaxel also activates MEK1 kinase leading to an elevation of ERK1 and ERK2 activity. MEK1 members are known to be critical for cell growth and proliferation in a number of systems. By using a combination of MEK inhibitors and paclitaxel, we were able to obtain greatly enhanced tumor killing by using suboptimal levels of the two drugs. Apoptosis in the presence of both drugs is five to tenfold more than with each drug alone. Additionally, we have also initiated an analysis of a derivative of epothilone B, dEpoB, which has similar effects as paclitaxel. We found that dEpoB also exhibits enhanced tumor killing activity in the presence of MEK inhibitor. DEpoB has the advantage over paclitaxel in that it is not transported by the multi-drug resistant transporter system, which allows many tumors to acquire chemotherapy-resistance. Thus, dEpoB may be effective where paclitaxel is not. Used in a clinical setting, these combinations may lower toxicity and enhance tumor killing. Accordingly, the four aims of this project are: (1) To determine if paclitaxel and an MEK inhibitor can cause enhanced tumor elimination in a preclinical model. (2) To similarly study the combined effects of dEpoB and an MEK inhibitor. (3) To use Affymetrix analysis and microchip arrays to identify genes that are altered by the use of these drug combinations. (4) In the event that Specific Aim (1) and/or Specific Aim (2) show efficacy in the preclinical models, we propose to initiate a clinical trial to test the effects of combination therapy studied in Specific Aims 1 and/or 2.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058223-09A1
Application #
6547633
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1992-09-30
Project End
2006-07-31
Budget Start
Budget End
Support Year
9
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820

Showing the most recent 10 out of 598 publications